Evidence map›Paper›PMID 25199094›Full record

ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2014

Efficacy of enrofloxacin in a mouse model of sepsis.

Andrea R Slate, Sheila Bandyopadhyay, Kevin P Francis, Mark G Papich, Brian Karolewski, Eldad A Hod, Kevin A Prestia

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. A New Antifungal-Loaded Sol-Gel Can PreventAntibiotics (Basel, Switzerland) · 2021
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Andrea R SlateDivision of Comparative Medicine, University of South Florida, Tampa, Florida, USA.
Sheila BandyopadhyayLaboratory of Transfusion Biology, Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Kevin P FrancisPerkin Elmer, Alameda, California, USA.
Mark G PapichDepartment of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina, USA.
Brian KarolewskiInstitute of Comparative Medicine, Columbia University, New York, New York, USA.
Eldad A HodLaboratory of Transfusion Biology, Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Kevin A PrestiaLaboratory of Transfusion Biology, Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York, USA; Institute of Comparative Medicine, Columbia University, New York, New York, USA.
Columbia University · USNorth Carolina State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examined the efficacy of enrofloxacin administered by 2 different routes in a mouse model of sepsis. Male CD1 mice were infected with a bioluminescent strain of enteropathogenic Escherichia coli and treated with enrofloxacin either by injection or in drinking water. Peak serum levels were evaluated by using HPLC. Mice were monitored for signs of clinical disease, and infections were monitored by using bioluminescence imaging. Serum levels of enrofloxacin and the active metabolite ciprofloxacin were greater in the group treated by injection than in controls or the groups treated by administration in drinking water. Survival of the group treated with enrofloxacin injection was greater than that of controls and groups treated with enrofloxacin in the drinking water. Bioluminescence in the group treated with enrofloxacin injection was less than that in the groups treated with oral administration at 12 h and in the groups treated orally and the control group at 16 h. According to these findings, we recommend the use of injectable enrofloxacin at 5 mg/kg SC for mice with systemic infections.

Indexed as

Administration, IntravenousAdministration, OralAnimalsAnti-Bacterial AgentsEnrofloxacinEscherichia coliEscherichia coli InfectionsFluoroquinolonesMaleMiceSepsisAnti-Bacterial AgentsEnrofloxacinFluoroquinolones

Identifiers

PMID25199094
PMCPMC4113238
OpenAlexW1415697615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.